Alnylam, Sarepta jump into Covid-19 game, as pandemic rekindles antiviral hopes of RNA-targeting technology

Jason Mast

Editor

The idea had been there from the beginning. Scientists, studying plants and worms at the turn of the 21st century, discovered a mechanism cells used …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alnylam, Sarepta jump into Covid-19 game, as pandemic rekindles antiviral hopes of RNA-targeting technology

Jason Mast

Editor

Sign up to read this article for free.

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Al­ny­lam, Sarep­ta jump in­to Covid-19 game, as pan­dem­ic rekin­dles an­tivi­ral hopes of RNA-tar­get­ing tech­nol­o­gy

Jason Mast

Editor

Sign up to read this article for free.

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

Alnylam, Sarepta jump into Covid-19 game, as pandemic rekindles antiviral hopes of RNA-targeting technology

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology